ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,615 | -22.3% | 427,979 | -11.9% | 0.02% | -10.5% |
| Q2 2023 | $14,940 | -17.5% | 486,007 | -3.4% | 0.02% | -20.8% |
| Q1 2023 | $18,119 | -7.9% | 502,887 | +1.0% | 0.02% | -11.1% |
| Q4 2022 | $19,683 | -99.9% | 498,042 | +0.8% | 0.03% | -6.9% |
| Q3 2022 | $19,858,000 | -8.8% | 494,235 | -4.6% | 0.03% | +3.6% |
| Q2 2022 | $21,770,000 | +41.8% | 517,851 | +31.4% | 0.03% | +75.0% |
| Q1 2022 | $15,350,000 | -0.5% | 394,001 | +1.8% | 0.02% | +6.7% |
| Q4 2021 | $15,426,000 | +8.7% | 387,110 | -1.4% | 0.02% | 0.0% |
| Q3 2021 | $14,191,000 | -7.2% | 392,681 | +5.3% | 0.02% | -6.2% |
| Q2 2021 | $15,284,000 | -5.7% | 372,877 | +0.4% | 0.02% | -11.1% |
| Q1 2021 | $16,205,000 | +137.2% | 371,500 | +172.2% | 0.02% | +125.0% |
| Q4 2020 | $6,832,000 | – | 136,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |